Tilray Inc (NASDAQ:TLRY) CFO Mark Castaneda sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $51.72, for a total value of $517,200.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Mark Castaneda also recently made the following trade(s):
- On Thursday, March 14th, Mark Castaneda sold 30,000 shares of Tilray stock. The stock was sold at an average price of $70.43, for a total value of $2,112,900.00.
Shares of Tilray stock opened at $50.68 on Thursday. The company has a quick ratio of 20.75, a current ratio of 21.37 and a debt-to-equity ratio of 2.17. Tilray Inc has a 52 week low of $20.10 and a 52 week high of $300.00. The company has a market capitalization of $4.72 billion and a price-to-earnings ratio of -61.80.
Institutional investors have recently made changes to their positions in the business. Toronto Dominion Bank acquired a new stake in Tilray in the fourth quarter valued at approximately $27,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Tilray in the fourth quarter valued at approximately $71,000. Bronfman E.L. Rothschild L.P. grew its stake in Tilray by 7,266.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,105 shares of the company’s stock valued at $78,000 after acquiring an additional 1,090 shares during the period. Captrust Financial Advisors acquired a new stake in Tilray in the third quarter valued at approximately $103,000. Finally, IFP Advisors Inc grew its stake in Tilray by 61.0% in the fourth quarter. IFP Advisors Inc now owns 1,729 shares of the company’s stock valued at $130,000 after acquiring an additional 655 shares during the period. 7.91% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have recently issued reports on TLRY shares. Zacks Investment Research downgraded Tilray from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th. Piper Jaffray Companies initiated coverage on Tilray in a research note on Wednesday, January 9th. They set an “overweight” rating and a $90.00 target price for the company. Seaport Global Securities initiated coverage on Tilray in a research note on Thursday, February 21st. They set a “neutral” rating and a $81.10 target price for the company. Roth Capital raised Tilray from a “neutral” rating to a “buy” rating in a research note on Wednesday, February 20th. Finally, Jefferies Financial Group initiated coverage on Tilray in a research note on Friday, March 8th. They set an “underperform” rating and a $61.00 target price for the company. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $106.52.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2019/04/18/tilray-inc-tlry-cfo-sells-517200-00-in-stock.html.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
See Also: What is Put Option Volume?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.